<DOC>
	<DOCNO>NCT02556801</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability demonstrate dose response signal use Total Symptom Score ( TSS ) , base challenge grass pollen Environmental Exposure Chamber ( EEC ) , follow estimation minimum effective dose SUBLIVAC FIX Phleum ( SP ) 10 month treatment compare placebo . The study 4 treatment group : 3 different dos SP placebo test .</brief_summary>
	<brief_title>SUBLIVAC Phleum Study</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<criteria>1 . Subjects sign informed consent . 2 . Subjects age ≥18 ≤65 year sign informed consent . 3 . Subjects least twoyear clinical history allergic rhinitis/rhinoconjunctivitis grass pollen , without concomitant asthma ( asthma must control ) . 4 . Subjects force expiratory volume one second ( FEV1 ) &gt; 70 % predict value measure screen document within 1 year study start . 5 . Subjects positive skin prick test ( SPT ) ( mean wheal diameter least 3 mm large negative control ; negative control &lt; 2 mm , histamine control positive ( mean wheal diameter least 3 mm large negative control ) ) grass pollen assess screen document positive response obtain within 1 year screening . 6 . Subjects grass pollen specific IgE great equal 0.7 kiloUnits ( kU ) /L assess screen document positive result obtain within 1 year screening . 7 . Subjects TSS least 10/24 baseline EEC challenge ( V2 ) combination staff assess score least 2/3 two objective TSS symptom ( i.e . run nose , sneeze red eye ) , baseline EEC challenge . 1 . Subjects ( expect ) clinically relevant symptom time schedule EEC assessment Visit 2 Visit 6 due concomitant sensitization i.e . positive SPT ( mean wheal diameter least 3 mm large negative control ) history allergic response causative allergen , discretion investigator . 2 . Patients grass pollen induce asthma . 3 . Subjects tolerate Baseline Challenge EEC . 4 . Subjects receive immunotherapy ( SCIT SLIT ) grass pollen allergen within past 5 year . 5 . ( Ongoing ) allergenspecific immunotherapy allergen ( ) study period . 6 . Subjects unsuccessful allergenspecific immunotherapy within past 5 year ( e.g. , limited , prematurely stop immunotherapy due noncompliance , AEs lack therapeutic effect ) , discretion investigator . 7 . Subjects undergo antiIgE therapy within 6 month prior inclusion and/or study . 8 . Subjects suffer severe immune disorder ( include autoimmune disease ) and/or disease require immunosuppressive drug . 9 . Subjects suffer active malignancy malignant disease ( except localize basal cell cancer skin long adequately treat recurrence within 3 month screen visit ) 5 year prior screen . 10 . Subjects suffer severe uncontrolled disease could increase risk participate study , include limited : cardiovascular insufficiency , severe unstable lung disease , endocrine disease , clinically significant renal hepatic disease , haematological disorder discretion Investigator . 11 . Subjects active inflammation infection target organ ( nose , eye low airway ) Visit 1 . 12 . Subjects suffer disease contraindication use adrenaline ( e.g . hyperthyroidism , glaucoma ) . 13 . Subjects receive vaccination within one week start therapy updosing phase . 14 . Subjects receive treatment systemic steroid within 4 week visit 1 and/or study . 15 . Subjects receive treatment systemic local βblockers anytime study . 16 . Subjects participate clinical study within last 3 month ( e.g . new investigational drug biological ) within last 30 day ( e.g . bioequivalent drug ) , discretion Investigator . 17 . Female subject childbearing potential pregnant , lactate use inadequate contraceptive measure ( adequate contraceptive measure : sexual abstinence ; oral contraceptive , trans dermal patch depot injection progestogen drug ( start least 4 week prior investigational medicinal product ( IMP ) administration ) ; double barrier method : condom occlusive cap ( diaphragm cervical/vault cap ) plus spermicidal agent ; intrauterine device ( IUD ) , intrauterine system ( IUS ) , implant , vaginal ring ( place least 4 week prior IMP administration ) ; male partner sterilization ( vasectomy documentation azoospermia ) prior female subject 's entry trial sole sexual partner female subject . 18 . Subjects history alcohol , drug medication abuse within past year study start . 19 . Subjects clinically relevant abnormal laboratory parameter screen . 20 . Subjects lack cooperation compliance , judge investigator . 21 . Subjects suffer severe psychiatric , psychological , neurological disorder . 22 . Subjects employee sponsor contract research organisation and/or 1st grade relative partner ( principal ) investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Sublingual immunotherapy</keyword>
	<keyword>Dose range find</keyword>
	<keyword>Grass pollen</keyword>
	<keyword>Allergic rhinitis/rhinoconjunctivitis</keyword>
	<keyword>Immunogenicity</keyword>
</DOC>